Table of Contents Author Guidelines Submit a Manuscript
Scientifica
Volume 2016, Article ID 4071735, 7 pages
http://dx.doi.org/10.1155/2016/4071735
Review Article

Polycystic Ovary Syndrome May Be an Autoimmune Disorder

Department of Immunology, University of Health Sciences, Lahore 54600, Pakistan

Received 2 December 2015; Revised 10 March 2016; Accepted 11 April 2016

Academic Editor: Malgorzata Wasniewska

Copyright © 2016 Hifsa Mobeen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. F. Stein and M. L. Leventhal, “Amenorrhea associated with bilateral polycystic ovaries,” American Journal of Obstetrics and Gynecology, vol. 29, no. 2, pp. 181–191, 1935. View at Publisher · View at Google Scholar
  2. M. Asunción, R. M. Calvo, J. L. San Millá N, H. F. Escobar-Morreale, J. Sancho, and S. Avila, “A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 7, pp. 2434–2438, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. P. G. Ovesen, N. Moller, and S. Greisen, “Polycystic ovarysyndrome clinical presentation and treatment,” Ugeskrift for Laeger, vol. 160, no. 3, pp. 260–264, 1998. View at Google Scholar
  4. M. A. Ganie and S. Kalra, “Polycystic ovary syndrome—a metabolic malady, the mother of all lifestyle disorders in women—can Indian health budget tackle it in future?” Indian Journal of Endocrinology and Metabolism, vol. 15, no. 4, pp. 239–241, 2011. View at Publisher · View at Google Scholar
  5. G. R. Mohan, “A case of poly cystic ovarian syndrome treated with Homoeopathy,” 2010, http://homoeocuredrmohan.blogspot.com/2013/10/a-case-of-poly-cystic-ovarian-syndrome.html.
  6. R. Azziz, E. Carmina, and D. Dewailly, “The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force,” Fertility and Sterility, vol. 91, pp. 456–488, 2009. View at Google Scholar
  7. S. S. Yen, P. Vela, and J. Rankin, “Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease,” The Journal of Clinical Endocrinology & Metabolism, vol. 30, no. 4, pp. 435–442, 1970. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Rebar, H. L. Judd, S. S. C. Yen, J. Rakoff, G. Vandenberg, and F. Naftolin, “Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome,” The Journal of Clinical Investigation, vol. 57, no. 5, pp. 1320–1329, 1976. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Waldstreicher, N. F. Santoro, J. E. Hall, M. Filicori, and W. F. Crowley Jr., “Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization,” Journal of Clinical Endocrinology and Metabolism, vol. 66, no. 1, pp. 165–172, 1988. View at Publisher · View at Google Scholar · View at Scopus
  10. R. P. Millar, A. J. Pawson, C. A. Flanagan, K. Morgan, and S. R. Maudsley, “Gonadotropin-releasing hormone receptor,” Endocrine Reviews, vol. 25, no. 2, pp. 235–275, 2004. View at Google Scholar
  11. H. Charlton, “Hypothalamic control of anterior pituitary function: a history,” Journal of Neuroendocrinology, vol. 20, no. 6, pp. 641–646, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. V. Meethal, T. Liu, H. W. Chan et al., “Identification of a regulatory loop for the synthesis of neurosteroids: a steroidogenic acute regulatory protein-dependent mechanism involving hypothalamic-pituitary-gonadal axis receptors,” Journal of Neurochemistry, vol. 110, no. 3, pp. 1014–1027, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. O. Lunde, P. Magnus, L. Sandvik, and S. Hoglo, “Familial clustering in the polycystic ovarian syndrome,” Gynecologic and Obstetric Investigation, vol. 28, no. 1, pp. 23–30, 1989. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Kurzrock and P. R. Cohen, “Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited,” Medical Hypotheses, vol. 68, no. 3, pp. 480–483, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Zavadilova, J. Vrbikova, M. Vankova et al., “Role of D327N sex-hormone binding globulin gene polymorphism in the pathogenesis of polycystic ovary syndrome,” Endocrine Abstracts, vol. 11, article 709, 2006. View at Google Scholar
  16. M. W. A. Angstwurm, R. Gärtner, and H. W. L. Ziegler-Heitbrock, “Cyclic plasma IL-6 levels during normal menstrual cycle,” Cytokine, vol. 9, no. 5, pp. 370–374, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. K. E. Sharquie, A. A. Al-Bayatti, A. I. Al-Ajeel, A. J. Al-Bahar, and A. A. Al-Nuaimy, “Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome,” Saudi Medical Journal, vol. 28, no. 7, pp. 1039–1043, 2007. View at Google Scholar · View at Scopus
  18. R. Azziz, E. Carmina, D. Dewailly et al., “Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 11, pp. 4237–4245, 2006. View at Publisher · View at Google Scholar
  19. J. Adams, S. Franks, D. W. Polson et al., “Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone,” The Lancet, vol. 2, no. 8469-8470, pp. 1375–1379, 1985. View at Publisher · View at Google Scholar · View at Scopus
  20. R. D. Sinclair and R. P. R. Dawber, “Androgenetic alopecia in men and women,” Clinics in Dermatology, vol. 19, no. 2, pp. 167–178, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Venkatesan, A. Dunaif, and A. Corbould, “Insulin resistance in polycystic ovarian syndrome: progress and paradoxes recent progress in hormone research,” Journal of Biomedicine and Biotechnology, vol. 56, pp. 295–308, 2001. View at Google Scholar
  22. S. M. Grundy, H. B. Brewer Jr., J. I. Cleeman, S. C. Smith Jr., and C. Lenfant, “Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition,” Circulation, vol. 109, pp. 433–438, 2004. View at Publisher · View at Google Scholar
  23. A. Kerchner, W. Lester, S. P. Stuart, and A. Dokras, “Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study,” Fertility and Sterility, vol. 91, no. 1, pp. 207–212, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Månsson, J. Holte, K. Landin-Wilhelmsen, E. Dahlgren, A. Johansson, and M. Landén, “Women with polycystic ovary syndrome are often depressed or anxious-a case control study,” Psychoneuroendocrinology, vol. 33, no. 8, pp. 1132–1138, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. W. Levinson, “Mycobacteria,” in Review of Medical Microbiology and Immunology, pp. 150–154, McGraw-Hill, New York, NY, USA, 2010. View at Google Scholar
  26. A. Huber, F. Menconi, S. Corathers, E. M. Jacobson, and Y. Tomer, “Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms,” Endocrine Reviews, vol. 29, no. 6, pp. 697–725, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. L. C. Kottyan, E. E. Zoller, J. Bene et al., “The IRF5-TNPO3 association with systemic lupuserythematosus has two components that other autoimmunedisorders variably share,” Human Molecular Genetics, vol. 24, no. 2, pp. 582–596, 2015. View at Publisher · View at Google Scholar
  28. C. Farquhar, “Introduction and history of polycystic ovary syndrome,” in Polycystic Ovary Syndrome, pp. 4–24, Cambridge University Press, Cambridge, UK, 2nd edition, 2007. View at Google Scholar
  29. R. Hart, “Definitions, prevalence and symptoms of polycystic ovaries and the polycystic ovary syndrome,” in Polycystic Ovary Syndrome, pp. 15–26, Anshan, Kent, UK, 2007. View at Google Scholar
  30. T. L. Marx and A. E. Mehta, “Polycystic ovary syndrome: pathogenesis and treatment over the short and long term,” Cleveland Clinic Journal of Medicine, vol. 70, no. 1, pp. 31–45, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. B. C. J. M. Fauser, B. C. Tarlatzis, R. W. Rebar et al., “Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group,” Fertility and Sterility, vol. 97, no. 1, pp. 28–38.e25, 2012. View at Publisher · View at Google Scholar
  32. J. Adams, D. W. Polson, and S. Franks, “Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism,” British Medical Journal, vol. 293, no. 6543, pp. 355–359, 1986. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Souter, L. A. Sanchez, M. Perez, A. A. Bartolucci, and R. Azziz, “The prevalence of androgen excess among patients with minimal unwanted hair growth,” American Journal of Obstetrics and Gynecology, vol. 191, no. 6, pp. 1914–1920, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. C. N. Wijeyaratne, A. H. Balen, J. H. Barth, and P. E. Belchetz, “Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among south Asians and Caucasians: is there a difference?” Clinical Endocrinology, vol. 57, no. 3, pp. 343–350, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Guastella, R. A. Longo, and E. Carmina, “Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes,” Fertility and Sterility, vol. 94, no. 6, pp. 2197–2201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS),” Human Reproduction, vol. 19, pp. 41–47, 2004. View at Google Scholar
  37. H. Teede, A. Deeks, and L. Moran, “Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan,” BMC Medicine, vol. 8, article 41, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Vrbikova and V. Hainer, “Obesity and polycystic ovary syndrome,” Obesity Facts, vol. 2, no. 1, pp. 26–35, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Lassmann and R. M. Ransohoff, “The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal,” Trends in Immunology, vol. 25, no. 3, pp. 132–137, 2004. View at Google Scholar
  40. L. Andréoletti, D. Hober, C. Hober-Vandenberghe et al., “Detection of Coxsackie B virus RNA sequences in whole blood samples from adult patients at the onset of type I diabetes mellitus,” Journal of Medical Virology, vol. 52, no. 2, pp. 121–127, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. M. A. M. Van Boekel and W. J. Van Venrooij, “Modifications of arginines and their role in autoimmunity,” Autoimmunity Reviews, vol. 2, no. 2, pp. 57–62, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. E. M. Shevach, “Regulatory T cells in autoimmmunity,” Annual Review of Immunology, vol. 18, no. 1, pp. 423–449, 2000. View at Publisher · View at Google Scholar
  43. A. Samsami Dehaghani, N. Karimaghaei, M. E. Parsanezhad, M. Malekzadeh, M. Mehrazmay, and N. Erfani, “Anti-nuclear antibodies in patients with polycystic ovary syndrome before and after laparoscopic electrocauterization,” Iranian Journal of Medical Sciences, vol. 38, no. 2, pp. 187–190, 2013. View at Google Scholar · View at Scopus
  44. R. Cervera, J. Font, M. Ramos-Casals et al., “Primary Sjogren's syndrome in men: clinical and immunological characteristics,” Lupus, vol. 9, no. 1, pp. 61–64, 2000. View at Publisher · View at Google Scholar
  45. P. Obermayer-Straub, C. P. Strassburg, and M. P. Manns, “Autoimmune hepatitis,” Journal of Hepatology, Supplement, vol. 32, no. 1, pp. 181–197, 2000. View at Google Scholar · View at Scopus
  46. A. K. Makled, H. M. Fathi, M. F. Gomaa, and R. M. Bakr, “Serologic markers of autoimmunity in women with polycystic ovary syndrome,” Middle East Fertility Society Journal, vol. 20, no. 2, pp. 86–90, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. D. S. Cooper, “Subclinical hypothyroidism,” The New England Journal of Medicine, vol. 345, no. 4, pp. 260–265, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. P. Saravanan and C. M. Dayan, “Thyroid autoantibodies,” Endocrinology and Metabolism Clinics of North America, vol. 30, no. 2, pp. 315–337, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Orgiazzi, “Anti-TSH receptor antibodies in clinical practice,” Endocrinology Metabolism Clinics of North America, vol. 29, no. 2, pp. 339–355, 2000. View at Publisher · View at Google Scholar
  50. C. M. Boyd and J. R. Baker, “The immunology of thyroid cancer,” Endocrinology Metabolism Clinics of North America, vol. 25, no. 1, pp. 159–179, 1996. View at Google Scholar
  51. R. D. Utiger, Werner and Ingbar's the Thyroid: A Fundamental and Clinical Text, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 9th edition, 2005.
  52. J. Petrikova, I. Lazurova, I. Dravecka et al., “The prevalence of non organ specific and thyroid autoimmunity in patients with polycystic ovary syndrome,” Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, vol. 159, no. 2, pp. 302–306, 2015. View at Publisher · View at Google Scholar
  53. M. Kachuei, F. Jafari, A. Kachuei, and A. H. Keshteli, “Prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome,” Archives of Gynecology and Obstetrics, vol. 285, no. 3, pp. 853–856, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Arduc, B. A. Dogan, S. Bilmez et al., “High prevalence of Hashimoto's thyroiditis in patients with polycystic ovary syndrome: does the imbalance between estradiol and progesterone play a role?” Endocrine Research, vol. 40, no. 4, pp. 204–210, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. O. E. Janssen, N. Mehlmauer, S. Hahn, A. H. Öffner, and R. Gärtner, “High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome,” European Journal of Endocrinology, vol. 150, no. 3, pp. 363–369, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. D. Sarkar, “Recurrent pregnancy loss in patients with thyroid dysfunction,” Indian Journal of Endocrinology and Metabolism, vol. 16, no. 2, pp. 350–351, 2012. View at Google Scholar
  57. A. Menteşe, S. Guven, A. Sumer et al., “Serum anti-carbonic anhydrase I and II antibodies and polycystic ovary syndrome,” Turkish Journal of Biochemistry, vol. 38, no. 1, pp. 43–48, 2013. View at Publisher · View at Google Scholar
  58. K. R. George and N. A. Malini, “Infertility in females in context of antispermantibodies in pelvic inflammatory disease (PID) andpolycystic ovarian syndrome (PCOS),” The Bioscan, vol. 7, no. 1, pp. 47–51, 2012. View at Google Scholar
  59. J. Petríková and I. Lazúrová, “Ovarian failure and polycystic ovary syndrome,” Autoimmunity Reviews, vol. 11, no. 6-7, pp. A471–A478, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. S. G. Gardner, E. A. Gale, A. J. Williams et al., “Progression to diabetes in relatives with islet autoantibodies. Is it inevitable?” Diabetes Care, vol. 22, no. 12, pp. 2049–2054, 1999. View at Publisher · View at Google Scholar
  61. D. A. Samsami, P. Razmjoei, and M. E. Parsanezhad, “Serum levels of anti-histone and anti-double-strand DNA antibodies before and after laparoscopic ovarian drilling in women with polycystic ovarian syndrome,” Journal of Obstetrics and Gynecology of India, vol. 64, no. 1, pp. 47–52, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. B. Hamedi, E. K. Sarvestani, A. Khalili et al., “Evaluation of ANA-related serologic autoantibodies in polycystic ovary syndrome,” Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, vol. 14, no. 1, pp. 21–25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. S. G. Gardener, E. A. M. Gale, A. J. K. Williams et al., “Progression to diabetes in relatives with islet autoantibodies. Is it inevitable?” Diabetes Care, vol. 22, no. 12, pp. 2049–2054, 1999. View at Google Scholar
  64. H. E. Lebovitz, “Adjunct therapy for type 1 diabetes mellitus,” Nature Reviews Endocrinology, vol. 6, no. 6, pp. 326–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Gottschau, S. K. Kjaer, A. Jensen, C. Munk, and L. Mellemkjaer, “Risk of cancer among women with polycystic ovary syndrome: a Danish Cohort study,” Gynecologic Oncology, vol. 136, no. 1, pp. 99–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. A. G. Renehan, M. Tyson, M. Egger, R. F. Heller, and M. Zwahlen, “Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies,” The Lancet, vol. 371, no. 9612, pp. 569–578, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. World Cancer Research Fund/American Institute for Cancer Research, Continuous Update Project Report. Food, Nutrition, Physical Activity, and the Prevention of Breast Cancer, American Institute for Cancer Research, Washington, Wash, USA, 2010.
  68. World Cancer Research Fund/American Institute for Cancer Research, Continuous Update Project Report. Food, Nutrition, Physical Activity, and the Prevention of Ovarian Cancer, WCRF, Washington, DC, USA, 2014.
  69. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote, “Endometrial cancer,” The Lancet, vol. 366, no. 9484, pp. 491–505, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. J. A. Barry, M. M. Azizia, and P. J. Hardiman, “Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis,” Human Reproduction Update, vol. 20, no. 5, Article ID dmu012, pp. 748–758, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. R. S. Legro, M31-PCOS: Use of Metformin to Allow Pregnancy: Other Treatments, Department of Obstetrics & Gynecology, Penn State College of Medicine, M.S. Hershey Medical Center, Hershey, Pa, USA, 2013. View at Publisher · View at Google Scholar
  72. H. J. Teede, M. L. Misso, A. A. Deeks et al., “Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline,” Medical Journal of Australia, vol. 195, no. 6, pp. S65–S112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. N. K. Stepto, S. Cassar, A. E. Joham et al., “Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp,” Human Reproduction, vol. 28, no. 3, pp. 777–784, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. M. I. Mezaal, M. I. Nader, and I. H. Aziz, “Molecular study of insulin resistance and polycystic ovary syndrome,” American Journal of Medicine and Medical Sciences, vol. 5, no. 3, pp. 121–125, 2015. View at Google Scholar
  75. H. F. Escobar-Morreale, B. Roldán, R. Barrio et al., “High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 11, pp. 4182–4187, 2000. View at Publisher · View at Google Scholar · View at Scopus
  76. J. F. Cara and R. L. Rosenfield, “Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells,” Endocrinology, vol. 123, no. 2, pp. 733–739, 1988. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Codner, N. Soto, P. Lopez et al., “Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 6, pp. 2250–2256, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. B. O. Yildiz, G. Bozdag, Z. Yapici, I. Esinler, and H. Yarali, “Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria,” Human Reproduction, vol. 27, no. 10, pp. 3067–3073, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. D. S. Kiddy, P. S. Sharp, D. M. White et al., “Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases,” Clinical Endocrinology, vol. 32, no. 2, pp. 213–220, 1990. View at Publisher · View at Google Scholar · View at Scopus
  80. M. W. O'Reilly, A. E. Taylor, N. J. Crabtree et al., “Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione,” Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 3, pp. 1027–1036, 2014. View at Publisher · View at Google Scholar · View at Scopus